重视肝硬化患者心肺功能状况的评估

doi:10.3969/j.issn.1672-5069.2015.05.001

Abstract

Liu Yulan. Cardiac and pulmonary functions in patients with liver cirrhosis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(5): 449-452.

[1] Ma ZH，Lee SS. Cirrhotic cardiopulmonary:getting to the heart of the matter. Hepatology，1996，14:606-608.
[2] Moller S，Krag A，Bendtsen F. Kidney injury in cirrhosis:pathophysiological and therapeutic aspects of hepatorenal syndromes. Liver Int，2014，34:1153-1163.
[3] Grace JA，Klein S，Herath CB，et al. Activation of the MAS receptor by angiotensin-（1-7） in the renin-angiotensin system mediates mesenteric vasodilatation in cirrhosis. Gastroenterology，2013，145:874-884.
[4] Wiese S，Hove JD，Bendtsen F，et al. Cirrhotic cardiomyopathy:pathogenesis and clinical relevance. Nat Rev Gastroenterol Hepatol，2014，11（3）:177-186.
[5] Blendis L，Wong F. Is there a cirrhotic cardiomyopathy. Am J Gastroenterol，2000，95:3026-3028.
[6] Fede G， Privitera G，Tomaselli T，et al. Cardiovascular dysfunction in patients with liver cirrhosis. Ann Gastroenterol，2015，28:31-40.
[7] Han S，Meller S，Bendtsen F，et al. Diurnal variation and dispersion in QT interval in cirrhosis:relation to haemodynamic changes. J Hepatol，2007，47（3）:373-380.
[8] Zambruni A，Trevisani F，Caraceni P，et al. Cardiac electrophysiological abnormalities in patients with cirrhosis. J Hepatol，2006，44:994-1002.
[9] Kennedy TC，Knudson RJ. Exercise-aggravated hypoxemia and orthodeoxia in cirrhosis. Chest，1977，72:305-309.
[10] Grace JA，Angus PW. Hepatopulmonary syndrome:update on recent advances in pathophysiology，investigation，and treatment. J Gastroenterol Hepatol，2013，28:213-219.
[11] Krowka MJ. Hepatopulmonary syndrome versus portopulmonary hypertension:distinctions and dilemmas. Hepatology，1997，25:1282-1284.
[12] Khan AN，Al-Jahdali H，Abdullah K，et al. Pulmonary vascular complications of chronic liver disease:Pathophysiology，imaging，and treatment. Ann Thorac Med，2011，6:57-65.
[13] Hoeper MM，Krowka MJ，Strassburg CP. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet，2004，363:1461-1468.
[14] 王爱鱼，侯培珍，高军. 肝硬化所致心脏损害-附96例尸解分析. 中华消化杂志，1998，18:184.
[15] Ruiz-del-Arbol L，Monescillo A，Arocena C，et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology，2005，42:439-447.
[16] Ruiz-del-Arbol L，Urman J，Fernandez J，et al. Systemic，renal， and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology，2003，38:1210-1218.
[17] Ronco C，Haapio M，House AA，et al. Cardiorenal syndrome. J Am Coll Cardiol，2008，52:1527-1539.
[18] Azoulay D，Castaing D，Dennison A，et al. Transjugular intrahepatic portosystemic shunt worsens the hyperdynamic circulatory state of the cirrhotic patient:preliminary report of a prospective study. Hepatology，1994，19:129-132.
[19] 王芳，刘玉兰，王岩，等. 肝硬化患者心功能的临床研究. 胃肠病学和肝病学杂志，2003，10（12）464-466.
[20] Chen B，Wang W，Tam MD，et al. Transjugular intrahepatic portosystemic shunt in liver transplant recipients:indications，feasibility，and outcomes. Hepatol Int，2015 9（3）:391-398.
[21] Rabie RN，Cazzaniga M，Salerno F，et al. The use of E/A ratio as a predictor of outcome in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt. Am J Gastroenterol， 2009，104:2458-2466.
[22] Fouad TR，bdel-Razek WM，Burak KW，et al. Prediction of cardiac complications after liver transplantation. Transplantation，2009，87:763-770.
[23] Fede G，Privitera G，Tomaselli T，et al. Cardiovascular dysfunction in patients with liver cirrhosis. Ann Gastroenterol，2015，28，31-40.
[24] Schenk P，Schoniger-Hekele M，Fuhrmann V，et al Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis. Gastroenterology，2003，125:1042-1052.
[25] Schenk P，Schoniger-Hekele M，Fuhrmann V，et al. Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis. Gastroenterology，2003，125:1042-1052.
[26] Palma DT，Philips GM，Arguedas MR，et al. Oxygen desaturation during sleep in hepatopulmonary syndrome. Hepatology，2008，47:1257-1263.
[27] Machicao VI，Balakrishnan M，Fallon MB. Pulmonary complications in chronic liver disease. Hepatology，2014，59:1627-1637.
[28] Swanson KL，Wiesner RH，Krowka MJ. Natural history of hepatopulmonary syndrome:impact of liver transplantation. Hepatology，2005，41:1122-1129.
[29] De BK，Dutta D，Pal SK，et al. The role of garlic in hepatopulmonary syndrome:a randomized controlled trial. Can J Gastroenterol，2010，24:183-188.
[30] Martinez-Palli G，Drake BB，Garcia-Pagan JC，et al. Effect of transjugular intrahepatic portosystemic shunt on pulmonary gas exchange in patients with portal hypertension and hepatopulmonary syndrome. World J Gastroenterol，2005，11:6858-6862.
[31] Gupta S，Castel H，Rao RV，et al. Improved survival after liver transplantation in patients with hepatopulmonary syndrome. Am J Transplant，2010，10:354-363.
[32] Hadengue A，Benhayoun MK，Lebrec D，et al. Pulmonary hypertension complication portal hypertension:prevalence and relation to splanchnic hemodynamic. Gastroenterology，1991，100:520-528.
[33] Torregrosa M，Genesca J，Gonzalez A，et al. Role of Doppler echocardiography in the assessment of portopulmonary hypertension in liver transplant candidates. Transplantation，2001，71:572-574.
[34] Krowka MJ，Pleak DJ，Findlay JY，et al.Pulmonary hemodynamics and perioperative cardiopulmonaryrelated mortality in patients with portopulmonary hypertension undergoing liver transplantation.Liver Transplant，2000，6:443-450.

Cardiac and pulmonary functions in patients with liver cirrhosis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhuang Ying, Lin Zhihui.. Clinical manifestations and diagnosis of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 765-767.
[2]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[3]	Wu Dan Ma Xiangying.. Insulin resistance,carotid atherosclerosis and left ventricular function in patients with NAFLD-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 876-879.
[4]	He Zhi’an, Yu Liping, Lai Jiangqiong, et al.. Evaluation of varices bleeding and portal vein thrombosis by ARFI in patients with cirrhosis and esophagogastric varices [J]. Journal of Practical Hepatology, 2019, 22(6): 888-891.
[5]	Wang Yueyuan, Wang Yan, Zhang Dandan. Short-term efficacy of terlipressin and octreotide combination in treatment of cirrhotic patients complicated by hepatorenal syndrome [J]. Journal of Practical Hepatology, 2019, 22(5): 684-687.
[6]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[7]	Dan Zhuyongji, Liu Zhilan, Lu Yanyan, et al. Efficacy of endoscopic sequential variceal 1igation plus sclerotherapy in treatment of patients with hepatitis B-induced liver cirrhosis complicated by esophageal gastric varices bleeding [J]. Journal of Practical Hepatology, 2019, 22(5): 692-695.
[8]	Huang Hanjun, Lu Fengrong, Zhang Can. Clinical value of MRI scanning based on exchange hemodynamics model in evaluating liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 696-699.
[9]	Zhao Fangfang, Zhai Yongzhen, Feng Guohe. Efficacy and safety of autologous peripheral blood stem cell transplantation in patients with hepatitis B cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 700-703.
[10]	Chen Shan, Zhuang Huashuai, Xing Yixi, et al. Preventive application of meropenem in patients with liver cirrhosis complicated by upper gastrointestinal bleeding [J]. Journal of Practical Hepatology, 2019, 22(5): 704-707.
[11]	Xu Qilin, Hao Shaohuan, Ran Bo. Risk factors of portal vein thrombosis after splenectomy in patients with liver cirrhosis and portal hypertension [J]. Journal of Practical Hepatology, 2019, 22(5): 708-711.
[12]	Jin Lianghong, Li Xingjie, Guan Hongbo, et al. Clinical value of dual-energy CT iodine quantification combined with dynamic contrast-enhanced MRI in evaluating hepatic hemodynamics and liver functions in patients with hepatitis B liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 712-715.
[13]	Bian Xinqu, Chen Jie, Liu Yanmin, et al. Serum thyroid hormone level changes in patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy [J]. Journal of Practical Hepatology, 2019, 22(5): 716-719.
[14]	Xiao Han, Wang Li. Mechanisms of thrombocytopenia in liver cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 462-465.
[15]	Han Meiling, Chen Ping. Antiviral therapy in patients with liver cirrhosis and thrombocytopenia [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 466-469.